Glen Eagle Advisors’s Fidelity Disruptive Medicine ETF FMED Stock Holding History

Glen Eagle Advisors’s Portfolio FMED Stock Details FMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.21K	Hold	90	–	–	﹤0.01%	841
2025 Q4	$2.44K	Hold	90	–	–	﹤0.01%	860
2025 Q3	$2.25K	Hold	90	–	–	﹤0.01%	884
2025 Q2	$2.16K	Hold	90	–	–	﹤0.01%	839
2025 Q1	$2.13K	Hold	90	–	–	﹤0.01%	839
2024 Q4	$2.22K	Hold	90	–	–	﹤0.01%	862
2024 Q3	$2.37K	Hold	90	–	–	﹤0.01%	883
2024 Q2	$2.17K	Hold	90	–	–	﹤0.01%	889
2024 Q1	$2.3K	Buy	+90	New	+$2.22K	﹤0.01%	889

Other funds holding FMED

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vise Technologies New York $5.09B AUM 22.62% 1-Year Est. Return

BXM Wealth Englewood, Colorado $184M AUM 36.28% 1-Year Est. Return

GJIA

Glass Jacobson Investment Advisors Owings Mills, Maryland $321M AUM 20.69% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $984M AUM 34.19% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Glen Eagle Advisors's FMED Position: Q1 2026 in Review

Glen Eagle Advisors held its Fidelity Disruptive Medicine ETF (FMED) position steady in Q1 2026 at 90 shares worth $2.21K. The position accounts for ﹤0.01% of the portfolio, ranked #841.

Glen Eagle Advisors first reported a position in FMED in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.44K in Q4 2025. 11 funds tracked by Wall St. Rank hold FMED as of Q1 2026.

Glen Eagle Advisors held 90 shares of Fidelity Disruptive Medicine ETF worth $2.21K as of Q1 2026.
Glen Eagle Advisors left its Fidelity Disruptive Medicine ETF share count unchanged in Q1 2026.
Fidelity Disruptive Medicine ETF made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #841 holding.
Glen Eagle Advisors first reported a position in Fidelity Disruptive Medicine ETF in Q1 2024 and has held it in 9 quarters since.
Glen Eagle Advisors's Fidelity Disruptive Medicine ETF position peaked at $2.44K in Q4 2025.
11 funds tracked by Wall St. Rank held Fidelity Disruptive Medicine ETF as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.